EU/3/14/1324

About

On 22 August 2014, orphan designation (EU/3/14/1324) was granted by the European Commission to DualTpharma B.V., the Netherlands, for 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethylsulfamide for the treatment of small cell lung cancer.

Key facts

Active substance
2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethylsulfamide
Disease / condition
Treatment of small cell lung cancer
Date of decision
22/08/2014
Outcome
Positive
Orphan decision number
EU/3/14/1324

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

DualTpharma B.V.
Bosschstraat 111 D 01
6211AW Maastricht
The Netherlands
Tel. +31 884 455666
Fax +31 884 455776
E-mail: info@dualtpharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating